RxDoctor Payments Data

Jerry Fan, MD

Cardiovascular Disease · Temple, TXNPI 1619405784

Payments from drug & device makers

$37,178in general payments, 2019–2025

Across 577 payments — averaging $64.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$7K
  • AstraZeneca$5K
  • Amgen$5K
  • Abiomed$3K
  • Medtronic$2K
  • Novartis$2K
  • plus $13K from 35 others

What the payments were for

  • Consulting fees$7,07419%
  • Travel & lodging$6,28417%
  • Food & beverage$23,13962%
  • Education$6812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,178 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$27,389
Medicare patients
382
Services billed
646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban18$18,174
Metoprolol Succinate45$762
Ranolazine ErRanolazine11$662
Atorvastatin Calcium46$658
ClopidogrelClopidogrel Bisulfate25$596
Losartan Potassium37$551
Rosuvastatin Calcium22$543
Carvedilol25$278
Spironolactone15$212
Lisinopril21$194
Ezetimibe15$190
Amlodipine Besylate17$104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$754$18,17418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Temple

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →